Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GRF312 5% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A: GRF312 5% administered b.i.d. (morning/evening) | EXPERIMENTAL | - |
| Group B: Vehicle administered b.i.d. (morning/evening) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GRF312 5% | DRUG | Immune Globulin (Human), (GRF312 5% Ophthalmic Solution |
| Placebo Comparator | OTHER | Vehicle. |
Inclusion criteria 3. Participant willing and able to self-administer eye drops, follow instructions during the Run-in Period and Treatment Period, and be present for the required visits for the duration of the study. 4\. Participant-reported history of DED in O.U. 5. History of non-prescription (o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
GRF312 5% is an investigational small molecule being developed for the treatment of Dry Eye Disease. It is a topical ophthalmic formulation currently in clinical development, though it is not yet approved by regulatory authorities.
GRF312 5% is being developed by Grifols, S.A., a biopharmaceutical company traded on the NASDAQ under the ticker GRFS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational treatment for Dry Eye Disease.
GRF312 5% is in Phase 2 clinical development. A Phase 2 trial has been completed, evaluating the safety, tolerability, and efficacy of the drug in participants with Dry Eye Disease. The drug remains investigational and has not received FDA approval.
GRF312 5% has been studied in one completed Phase 2 clinical trial, identified as NCT07264517. This randomized, double-blind, placebo-controlled trial enrolled 103 participants with Dry Eye Disease in the United States, with a minimum age of 18 years.
GRF312 5% is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Dry Eye Disease. The completed Phase 2 trial assessed its safety and efficacy, but the drug has not yet received regulatory approval for commercial use.